Medpace Holdings Q1 FY26 earnings call MEDP

Medpace experienced a challenging Q1 FY26 with backlog cancellations reaching their highest point in over a year, contributing to a net book-to-bill ratio of 0.88. Management attributed these cancellations primarily to product performance and re-prioritizations, rather than acute financial shortages. Oncology and cardiovascular were identified as the largest therapeutic areas affected. Gross bookings were also weak, further impacting the net book-to-bill, despite strong win rates on initial award notifications.

Addressing market concerns regarding GLP-1 volatility, Medpace clarified that its metabolic therapeutic area historically exhibits the lowest cancellation rate among its segments. Management does not perceive increased volatility or higher cancellations in this area, noting that GLP-1 related work remains a 'pretty safe therapeutic area.' While new opportunities might be influenced by market saturation, existing programs are progressing as expected.

Despite the headwinds from elevated cancellations and a sub-1.0 book-to-bill, Medpace reconfirmed its full-year 2026 revenue guidance. The company projects that approximately $1.94 billion of its $2.9 billion ending backlog as of March 31, 2026, will convert to revenue in the next 12 months. Q1 FY26 backlog conversion stood at 23.3% of the beginning backlog, signaling confidence in the current guidance despite potential for no sequential revenue growth later in the year.

RFP volumes were down sequentially and year-over-year in Q1 FY26. However, management emphasized the quality of opportunities over numerical volume, stating that the current trend of high-quality RFPs is good and not indicative of widespread funding problems. The competitive landscape is acknowledged, but no significant change in competitiveness was noted, with the company focusing on improving its win rate.

Biopharma M&A activity, particularly large pharma acquiring biotech clients, generally poses a negative impact for Medpace, often resulting in the loss of future work and sometimes even ongoing projects. Regarding Artificial Intelligence, the company reiterated its stance that significant investment will be required over the next two years, with net benefits in efficiency not expected for several years due to the substantial upfront investment needed to leverage AI's potential.

Medpace maintains its strategic focus on small to mid-sized biotech clients, deliberately avoiding the large pharma segment due to differing service delivery models and requirements. The company announced the departure of President Jesse Geiger, with CEO August Troendle temporarily reassuming the President duties. This transition is expected to be seamless, supported by a strong and deep management team.